Welcome to our dedicated page for Royalty Pharma news (Ticker: RPRX), a resource for investors and traders seeking the latest updates and insights on Royalty Pharma stock.
Royalty Pharma plc reports developments tied to its biopharmaceutical royalty portfolio and life-sciences funding model. The company acquires existing royalties from medicine innovators and enters direct funding arrangements, including co-funding for late-stage clinical trials and product launches, in exchange for future royalties.
Recurring news covers Portfolio Receipts, Royalty Receipts, operating cash flow, guidance, dividends, royalty transactions, and updates from commercial products and development-stage candidates. Company announcements also address R&D funding collaborations, portfolio clinical and regulatory developments, leadership additions in partnering and technology, investor conference appearances, and scientific initiatives such as the Royalty Pharma Translational Prize.
Royalty Pharma (RPRX) reported Q3 2022 results showing net cash from operations of $539 million, up 15% year-over-year. Adjusted Cash Receipts increased 2% to $597 million. The company raised its full-year guidance for Adjusted Cash Receipts to between $2,750 million and $2,800 million, reflecting positive performance driven by royalty acquisitions and existing product sales, particularly in the cystic fibrosis and oncology sectors. Notably, transactions year-to-date have reached $3.0 billion, highlighting ongoing growth and market demand.
Royalty Pharma plc (RPRX) will announce its third quarter 2022 financial results on November 8, 2022, before U.S. markets open. A conference call will follow at 8:00 a.m. Eastern Time, accessible via the company's website. Royalty Pharma specializes in acquiring biopharmaceutical royalties and funding innovation in the sector, holding royalties on over 35 commercial products. These include notable therapies like Vertex's Trikafta and Biogen's Tysabri. For further details, visit the company's investors page.
The board of directors of Royalty Pharma plc (RPRX) has declared a fourth quarter 2022 dividend of $0.19 per Class A ordinary share. This dividend will be disbursed on December 15, 2022, to shareholders who are on record by the close of business on November 18, 2022. Royalty Pharma, founded in 1996, is a significant player in the biopharmaceutical industry, known for acquiring royalties and funding innovations aimed at advancing treatments. The company boasts a diverse portfolio, which includes royalties from over 35 leading therapies.
Royalty Pharma has announced key changes to its leadership team, appointing Art McGivern as Executive Vice President, Investments & General Counsel, while promoting George Lloyd to Executive Vice President, Investments & Chief Legal Officer. McGivern joins from Goodwin Procter with extensive experience in transaction structuring in the life sciences sector. Lloyd, who has been with the company since 2011, will oversee the legal team as responsibilities increase due to the complexity of transactions. These changes aim to enhance Royalty Pharma's capacity to navigate its growing transaction pipeline.
Royalty Pharma has partnered with Merck to co-fund the development of MK-8189, an investigational oral PDE10A inhibitor for treating schizophrenia. Royalty Pharma will provide $50 million upfront, with an option for an additional $375 million if Merck proceeds to Phase 3 trials. This unique collaboration showcases Royalty Pharma's commitment to innovative funding solutions and reflects the unmet need for new schizophrenia treatments. The partnership positions Royalty Pharma as a key player in biopharmaceutical funding, enhancing its pipeline of promising therapies.
Royalty Pharma plc (Nasdaq: RPRX) is set to participate in several investor conferences this September. Key dates include Citi’s 17th Annual BioPharma Conference on September 8 at 11:20 a.m. ET, Morgan Stanley’s Global Healthcare Conference on September 12 at 10:30 a.m. ET, and Bank of America’s Healthcare Conference on September 15 at 10:55 a.m. ET. Webcasts will be available on Royalty Pharma’s Events page and archived for thirty days. The company, established in 1996, is the leading buyer of biopharmaceutical royalties, focusing on funding innovation across the industry.
Royalty Pharma (Nasdaq: RPRX) reported strong financial results for Q2 2022, highlighting an 8% increase in net cash from operating activities to $575 million and a 10% rise in Adjusted Cash Receipts to $524 million. The company announced transactions totaling $2.5 billion year-to-date, enhancing its royalty portfolio with significant acquisitions including GSK's Trelegy, while raising its 2022 guidance for Adjusted Cash Receipts to $2,275-$2,350 million. CEO Pablo Legorreta emphasized strong market positioning and growth potential, despite a decline in total revenues by 3% to $536 million.
In the second quarter of 2022, Innoviva reported a 7% increase in royalties to $111.7 million, with significant contributions from GSK's products. However, income from operations fell by 14% to $82.6 million due to Entasis' operating expenses. The company completed the acquisition of Entasis for $42 million and a merger agreement with La Jolla Pharmaceutical for $6.23 per share, enhancing long-term growth prospects. Innoviva sold a 15% stake in Theravance for $282 million, bolstering its cash position to $283.6 million as of June 30, 2022.
The board of directors of Royalty Pharma (RPRX) has declared a third-quarter dividend of $0.19 per Class A ordinary share. This dividend will be paid on September 15, 2022, to shareholders on record by the close of business on August 19, 2022. Royalty Pharma, a leader in biopharmaceutical royalties, supports innovation across the industry and has a portfolio that includes royalties on approximately 35 commercial products, enhancing shareholder value.
Royalty Pharma (Nasdaq: RPRX) announced its second quarter 2022 financial results will be reported on August 4, 2022, before U.S. market open. A conference call and webcast will follow at 8:00 a.m. Eastern Time. Royalty Pharma is the largest biopharmaceutical royalty buyer and a leading funder of innovation in the industry. Its portfolio includes royalties from 35 commercial products, including therapies from AbbVie, Johnson & Johnson, and Biogen. The company partners with various entities to fund clinical trials and product launches.